Stock Insider Trading (from SEC Form 4)

XENT / Intersect ENT, Inc. insiders include Kaufman Richard E (Sr VP& Chief Operating Officer), Tansey Casey M (), Wolbeck Amy (V.P. Regulatory Affairs & Qlty), Earnhardt Lisa D (President and CEO), Matteucci Paul A, MOLL FREDERIC H (), KPCB XI Associates, LLC, and KLEINER PERKINS CAUFIELD & BYERS XI-A LP VERNON W ANTHONY (), Lucchese Cynthia L (), HILLEMAN JERYL L (Chief Financial Officer), ROOT JONATHAN D, LIDDLE DAVID E, KRAUSZ STEVEN M, FEDERMAN IRWIN, Stambaugh James (VP Clinical Affairs), de Clercq Casper L., U S Venture Partners IX L P, Mead Dana G Jr. (), Parker Drake R. (Chief Business Officer), CARSCADDEN GWEN R. (Chief People Officer), KLEINER PERKINS CAUFIELD & BYERS XI B LP, Lehman David Aaron (General Counsel), GALLAHUE KIERAN (), YOUNG PHILIP M, Presidio Management Group IX, L.L.C., .

Intersect ENT, Inc. insider trades are found here. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

Job titles are listed as of the filing and may not be current. Click the link icon to see the full transaction history.

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.
Latest
File Date
Latest
Tran Date
Insider Code Shares Post Shares Percent
Change
Share
Price
Tran Value Post Value Percent
Change
2018-02-16 2018-02-15 Earnhardt Lisa D President and CEO, Director
S -15,000 510,865 -2.85 36.3959 -545,938 18,593,391 -2.94
2018-02-07 2018-02-06 HILLEMAN JERYL L Chief Financial Officer
S -12,833 12,932 -49.81 35.7979 -459,394 462,938 -99.23
2018-02-05 2018-02-01 Kaufman Richard E Sr VP& Chief Operating Officer
S -958 87,512 -1.08 37.2106 -35,648 3,256,374 -1.09
2018-01-19 2018-01-17 Lehman David Aaron General Counsel
A 7,500 15,213 97.24
2018-01-19 2018-01-17 CARSCADDEN GWEN R. Chief People Officer
A 5,300 9,156 137.45
2018-01-19 2018-01-17 Parker Drake R. Chief Business Officer
A 3,000 3,000
2017-11-20 2017-11-20 MOLL FREDERIC H Director
S -2,500 239,624 -1.03 28.758 -71,895 6,891,107 -1.04
2017-06-05 2017-06-01 Mead Dana G Jr. Director
A 2,546 8,242 44.70
2017-06-05 2017-06-01 VERNON W ANTHONY Director
A 2,546 2,546
2017-06-05 2017-06-01 Tansey Casey M Director
A 2,546 2,546
2017-06-05 2017-06-01 Lucchese Cynthia L Director
A 2,546 7,546 50.92
2017-06-05 2017-06-01 GALLAHUE KIERAN Director
A 2,546 10,546 31.82
2016-09-08 2016-09-07 Wolbeck Amy V.P. Regulatory Affairs & Qlty
S -8,664 5,700 -60.32 15.6707 -135,771 89,323 -152.00
2016-09-07 2016-09-06 Stambaugh James VP Clinical Affairs
S -3,700 20,000 -15.61 16.00 -59,200 320,000 -18.50
2015-05-14 2015-05-12 de Clercq Casper L. Director
J -224,436 600,120 -27.22
2015-05-12 2015-05-11 KLEINER PERKINS CAUFIELD & BYERS XI-A LP 10% Owner
KLEINER PERKINS CAUFIELD & BYERS XI B LP 10% Owner
KPCB XI Associates, LLC 10% Owner
J -800,000 1,748,589 -31.39
2015-05-11 2015-05-08 Presidio Management Group IX, L.L.C. 10% Owner
U S Venture Partners IX L P 10% Owner
FEDERMAN IRWIN 10% Owner
KRAUSZ STEVEN M 10% Owner
LIDDLE DAVID E 10% Owner
Matteucci Paul A 10% Owner
ROOT JONATHAN D 10% Owner
YOUNG PHILIP M 10% Owner
J -990,000 1,995,433 -33.16
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related News Stories

Intersect ENT (XENT) SINUVA Implant Receives FDA Approval

2017-12-13 zacks
Intersect ENT, Inc. (XENT - Free Report) received approval from the FDA for SINUVA Sinus Implant. The company has been focused on developing innovative therapies for chronic sinusitis patients. (66-0)

BRIEF-‍James Flynn​ reports 5.92 pct passive stake in Intersect ENT

2017-11-16 reuters
* ‍James Flynn​ reports 5.92 percent passive stake in Intersect ENT as of Nov 6 - SEC filing Source text : (bit.ly/2jwmJXW) Further company coverage:

BRIEF-FDA performs pre-approval inspection of Intersect ENT's menlo park facility

2017-11-06 reuters
* Intersect ENT Inc - ‍FDA has set a pdufa target action date of January 7, 2018​

Intersect ENT's (XENT) CEO Lisa Earnhardt on Q3 2017 Results - Earnings Call Transcript

2017-11-04 seekingalpha
Good afternoon, and welcome to the Intersect ENT Third Quarter 2017 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. Please note that this event is being recorded.

Your Daily Pharma Scoop: AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?

2017-10-18 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (389-2)

The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT

2017-10-11 zacks
Chicago, IL – October 11, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include IDEXX Laboratories, Inc. (Nasdaq:(IDXX - Free Report)  – Free Report), Steris Corp. (NYSE:(STE - Free Report)  – Free Report), K2M Group Holdings, Inc. (195-0)

5 MedTech Stocks for Stellar Returns in Q3

2017-10-10 zacks
While the Wall Street is gearing up for the third-quarter releases, the Republicans have lost another battle pertaining to the repeal of Affordable Care Act (ACA), or Obamacare, with the recent Graham-Cassidy bill defeat. (76-0)

The Saga to Revoke Obamacare Continues: 3 MedTech Picks

2017-10-05 zacks
Trump’s failure to pass the Graham-Cassidy bill, which was targeting the termination of the Obamacare Act and seeking to replace it with a block grant of health care expenses for states every year, had stolen the limelight of late. (38-0)